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Abstract: The prevalence of hypertension has increased at an accelerated rate in older children 
and adolescents. This has raised great concern about premature development of cardiovascular 
disease, which has major long-term health and financial implications. While obesity and sedentary 
habits largely explain this phenomenon, there are other social and cultural influences that may 
unmask genetic susceptibility to hypertension in the pediatric population. While it is essential 
to exclude numerous causes of secondary hypertension in every child, these disorders are not 
discussed in this review. Rather, the aim of this review is to familiarize pediatricians with casual 
and ambulatory blood pressure measurement, epidemiology, pathophysiology, and management 
of several common conditions that play a role in the development of hypertension in children 
and adolescents. Besides primary hypertension and obesity-related hypertension, emphasis is 
given to epidemiology, measurement of blood pressure, including ambulatory blood pressure 
monitoring, hypertension associated with drug use, teenage pregnancy, and video and computer 
games. Lastly, because pediatricians are increasingly confronted with special issues concerning 
the management of the hypertensive athlete, this topic is also addressed.
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Introduction
The prevalence of secondary hypertension has increased only marginally as a result of 
measurement of blood pressure by pediatricians at more regular intervals. However, 
the prevalence of primary hypertension has increased from 1.0% to 4.5% over the 
period 1993–2004.1–6 Environmental and social factors leading to obesity are largely 
responsible for this alarming rise in the prevalence of primary hypertension. A culture 
of excessive television viewing and video and computer gaming leading to sedentary 
habits, high consumption of calories, salt and caffeine, and recreational drug use are 
among other leading contributors to this trend. These influences, coupled with a genetic 
predisposition to hypertension, are a recipe for cardiovascular injury during childhood 
or in early adulthood. Thus, hypertension is increasingly viewed as a continuum, 
with many similarities and considerations being applicable to older children as those 
recommended for adults with hypertension.7 Moreover, the long-term cardiovascular 
morbidity, mortality, and cost of undiagnosed hypertension and of uninterrupted 
unhealthy lifestyle habits leading to primary hypertension in the pediatric age group, 
are incalculable.
A comprehensive review of the causes, pathophysiology, and pharmacotherapy 
of secondary hypertension in children is beyond the scope of this review. However, 
the reader is referred to several such reviews.8–10 The focus of the current report is to 
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discuss selectively several special aspects of hypertension 
pertinent to older children and adolescents, in which the role 
of pediatricians in the recognition, prevention, evaluation, 
and management is essential. These disorders include primary 
hypertension and the influence of obesity, dietary, and other 
lifestyle measures; hypertension associated with use or abuse 
of prescribed or illicit drugs; hypertension associated with 
teenage pregnancy; and the emerging influence of video 
and computer games on the development of hypertension. 
We also discuss the evaluation and management of the 
hypertensive athlete, which presents unique challenges in 
the adolescent population.
Blood pressure measurement
The proper measurement of blood pressure in children 
and definitions of hypertension are detailed in excellent 
publications by several task forces.11–13 The Fourth Report 
from the National High Blood Pressure Program Working 
Group on Children and Adolescents is a cornerstone in the 
education of pediatricians on this increasingly important 
topic.11 The latest 2004 report emphasizes the need to mea-
sure blood pressure not only in children with conditions 
predisposing to hypertension, but in all children over three 
years of age. It also redefines the reference range between 
blood pressure $ the 90th percentile and , the 95th per-
centile from “high normal” to “prehypertension”. The latter 
definitions parallel the definitions established by a task force 
addressing hypertension in adults,7 and implies the need 
for preventive counseling and for taking appropriate steps 
to identify target organ injury, even at this early stage. This 
evidence-based report also stressed obesity as a key contribu-
tor to primary hypertension in children. Another seminal 
report emphasized the unquestioned value of characterizing 
blood pressure by ambulatory blood pressure monitoring 
(ABPM) in children suspected of having “white coat” or 
“masked” hypertension (see ABPM section).13
On a practical level, there are multiple devices that may 
be used for screening of hypertension. Wrist or finger devices 
have not been well validated and are not recommended. 
Table 1 indicates the advantages and disadvantages of these 
methods. Oscillometric devices, such as the Dinamap®, used 
in many hospitals and clinics, provide reliable measurements 
but are expensive. They are particularly useful in infants 
and younger children in whom manual blood pressure 
measurement by auscultation of Korotkoff sounds may be 
difficult. Blood pressure obtained by oscillatory measurement 
tends to be 5–10 mmHg higher than auscultatory or manual 
blood pressure measurement. Therefore, if these blood 
pressures are normal for age, gender, and height, they suffice 
for screening and for excluding hypertension. In contrast, 
oscillometric blood pressure values $ the 95th percentile 
must be confirmed by manual measurement in the upper and 
lower extremities utilizing an appropriate size cuff, because 
this method is more accurate and correlates best with the 
blood pressure norms that were originally compiled based 
on manual blood pressure measurements. If blood pressure is 
elevated, it should be repeated and the average of three such 
manual values during a single clinic visit may be recorded as 
the representative blood pressure for the child. Such children 
then undergo further screening for hypertension on three 
consecutive visits one week apart, because on rescreening, 
the prevalence of hypertension falls from 19% to 4.5%.3
 Table 2 summarizes the definitions of hypertension based 
on casual manual blood pressure measurements. If the blood 
pressure remains $ the 95th percentile, referral to a pediatric 
nephrologist or cardiologist who specializes in the evaluation 
and management of hypertension is recommended. The task 
is then to exclude secondary causes of hypertension which 
predominate in preadolescent children, and may require 
extensive investigation and unique therapies.
 In order to detect white coat or masked hypertension, the 
use of ABPM is essential. Table 3 summarizes the definitions 
of hypertension based on normative ABPM data obtained in 
949 healthy white German school children aged 5–20 years.14 
White coat hypertension is defined by casual office or clinic 
blood pressure . the 95th percentile but normal blood 
pressure by ABPM, while masked hypertension is defined 
as the converse of white coat hypertension. Because target 
organ injury depends largely on the average blood pressure 
load, this may be the best measure of hypertension and is 
Table 1 Advantages and disadvantages of automated and manual 
methods used to measure blood pressure
Automated/oscillometric Manual
• Pros
– Ease of use
– Good for screening
– Home use
– infants/small children
– Repeated measures
– Not affected by cuff placement
– wrist cuff available
• Cons
–  Measures mean arterial pressure  
then calculates systolic and diastolic  
blood pressure
– Manufacturer variability
– vibrations
• Pros
– Most accurate
–   Good for confirming  
hypertension
• Cons
– Observer error
– Noise interference
– Motion interference
–   Difficult in infants/ 
small children
–  Mercury:  
environmental hazard
–  Aneroid: loses accuracy  
over time
Adolescent Health, Medicine and Therapeutics 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
47
Hypertension in older children and adolescents
also based on ABPM measurement. However, currently there 
is no consensus of a blood pressure load cutoff value that 
defines hypertension in children. Because the value of ABPM 
is increasingly recognized and this method is underutilized, 
it is further discussed here.
Ambulatory blood pressure 
monitoring
ABPM is a tool that offers better sensitivity and specificity 
in the diagnosis of hypertension. It is becoming a standard 
of care at many centers offering expertise in pediatric 
hypertension, and is invaluable in pediatric hypertension 
research. The monitor can be routinely used in children 
over five years of age.13 ABPM consists of an appropriate-
sized blood pressure cuff placed on an upper extremity and 
a monitor worn on a patient’s belt. The monitor takes and 
records blood pressure usually continuously for 24 hours. 
Typically ABPM records blood pressure every 15–30 minutes 
during awake hours and every 20–60 minutes during sleep 
hours, and the data are analyzed in relation to a timed 
activity diary recorded by the family.13 Readings can take 
place during usual adolescent activities, including going to 
school, doing homework,  eating, and nonvigorous activity, 
like walking and sleeping. Activities not permitted while 
on ABPM include vigorous exercise, showering, bathing, 
and swimming. Commercially available monitors weigh as 
little as 168–457 g.13 When 24-hour ABPM is used, much 
richer data are available to the medical evaluator compared 
with casual blood pressure and self-monitored home blood 
pressure; these data include the influence of activities on 
blood pressure, mean 24-hour  systolic and diastolic blood 
pressures, mean awake systolic and diastolic blood pressures, 
mean sleep systolic and diastolic blood pressures, nocturnal 
dipping, and blood pressure load. Nocturnal dipping refers to 
physiological reduction in blood pressure while asleep, and is 
defined as a percentage: ([mean awake blood pressure - mean 
sleep blood pressure]/mean awake blood pressure) × 100. 
Normal nocturnal dipping is defined as $10%.15 Blood 
pressure load is defined as the percentage of valid blood 
pressure measurements above a set threshold value, usually 
the 95th percentile for age, gender, and height.16 Presently, 
there is no blood pressure load cutoff percentage that defines 
a normal pediatric population. However, a blood pressure 
load .25% is suggestive of hypertension, while a blood 
pressure load .50% is associated with an increased risk for 
target organ damage.13
Because of the wealth of data provided by ABPM, 
including the ability to assess nocturnal dip and blood 
Table 2 Hypertension classification by casual blood pressure measurement, frequency of measurement, and therapy recommendations*
Prehypertension Stage I hypertension Stage II hypertension
Systolic BP 
or diastolic 
BP percentile
90–94th percentile or  
if BP exceeds 120/80 mmHg  
even if <90th percentile
Systolic BP or diastolic BP  
95–99th percentile plus 5 mmHg
Systolic BP or diastolic BP 
percentile >99th percentile 
plus 5 mmHg
Frequency of BP 
measurement
Recheck in six months Recheck in 1–2 weeks or sooner; if child is 
symptomatic; if hypertension is persistent, 
evaluate on 2 additional occasions or refer  
to a specialist within one month 
Evaluate or refer to source of care 
within one week, or, immediately if 
the child is symptomatic
Therapeutic 
lifestyle changes
weight management counseling if 
overweight; introduce physical 
activity and diet management
weight management counseling if 
overweight; introduce physical activity  
and diet management
weight management counseling if 
overweight; introduce physical 
activity and diet management
Pharmacologic 
therapy
None, unless there are compelling 
indications such as chronic kidney 
disease, diabetes mellitus, heart 
failure, or left ventricular hypertrophy 
initiate therapy if the child has: symptoms 
secondary hypertension, hypertensive target 
organ injury, diabetes (type 1 or 2), or 
persistent hypertension despite 
nonpharmacological measures
initiate therapy
Note: *All reference limits are based on gender, age and height for casual BP measurement.11 
Abbreviation: BP, blood pressure.
Table 3 Classification of  blood pressure  by ABPM  in  children 
and adolescents*
• Normal BP: ,90th percentile by ABPM
• Hypertension: $95th percentile by ABPM
•  white coat hypertension: Casual BP $ 95th percentile in medical 
setting but casual BP or ABPM # 95th percentile
•  Masked prehypertension: Casual BP , 90th percentile in the medical 
setting but BP at 90–94th percentile by casual BP or by ABPM
•  Masked hypertension: BP , 90th percentile by casual BP in medical 
setting but BP $ 95th percentile by casual BP or by ABPM
•  Blood pressure load: 20%–50% systolic and/or diastolic BP by ABPM 
values above reference percentile¥
Notes: *ABPM reference limits;14 ¥no consensus on definition of hypertension based 
on blood pressure load. 
Abbreviations: BP, blood pressure; ABPM, ambulatory blood pressure monitoring.
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pressure load, ABPM is the only reliable study to separate 
properly patients with sustained hypertension from those 
with white coat hypertension and to “unmask” masked 
hypertension in those who have normal casual blood pressure. 
For example, among 118 children aged 3–19 years with 
chronic kidney disease, 46 patients were suspected of having 
hypertension based on casual blood pressure. When ABPM 
was used, 27 of these 46 patients were diagnosed as having 
white coat hypertension.17 Conversely, ABPM “unmasked” 
five patients who were deemed to have normal blood pressure 
by both casual and home self-measured blood pressure, 
 meaning one in five patients diagnosed as hypertensive by 
ABPM would have been missed even with use of both casual 
and self-measured blood pressure.17
Parallel with adult studies, more recent pediatric ABPM 
studies have shown a correlation between higher ABPM 
values and target organ hypertensive changes, including 
increased left ventricular mass index18,19 and increased carotid 
intima-media thickness,20 a known risk factor for stroke in 
adults. Lastly, ABPM may be a cost-effective tool in pediatric 
hypertension evaluation because it may eliminate the need 
for unnecessary studies. One recent pediatric study from a 
large referral center estimated a saving of $2.4 million/1000 
patients with the use of ABPM in evaluation of elevated 
blood pressure.21
Thus far, ABPM appears to be a very useful tool in 
blood pressure evaluation and management in the pediatric 
age group including adolescents, and there are a number of 
challenges and future study opportunities. These include 
derivation of normative data in healthy nonwhite populations 
based on larger data sets, information relating ABPM to well-
defined or intermediate end points in youth with sustained 
hypertension, correlation between treatment efficacy by 
ABPM measurements and reversal of target organ damage, 
and evidence-based schema for staging of ABPM levels.13 
Lastly, a recent report suggests that the process of monitoring 
blood pressure by ABPM may artificially blunt nocturnal 
dipping in a study of 103 veterans with chronic kidney 
disease.22 Thus, studies with similar design will need to be 
performed in children and adolescents to determine whether 
ABPM itself can induce abnormal nocturnal dipping.
Prevalence of hypertension  
and target organ damage
The previous misconception that hypertension is rare in 
children has been dispelled. Recent epidemiologic data 
indicate that the prevalence of hypertension has increased 
from 1% to 4.5% over the 1993–2004 period.1–6 In adolescents, 
the prevalence of hypertension is estimated to be 5%.3,6,23,24 
An increased awareness and detection of this disorder by 
pediatricians and school nurses accounts for only a small 
fraction of this increased prevalence of hypertension. 
Also, in the past, the association between hypertension and 
cardiovascular risk occurring during childhood was mostly 
conjectured or implied. However, more recent studies indicate 
that arteriolar changes, left ventricular hypertrophy, athero-
sclerosis, and increased carotid intima-media thickness may 
be detected in the childhood age group and are no longer lim-
ited to the adult population.13,18,25–28 Moreover, an increasing 
number of children present with overt hypertensive symptoms 
and signs comprising encephalopathy/headache, seizures 
and congestive heart failure, previously encountered almost 
exclusively in hypertensive adults.
The prevalence of white coat hypertension in children and 
adolescents evaluated in the setting of hypertension clinics 
ranges from 13% to 88%.29–31 Left ventricular mass index tends 
to be higher in adolescents with white coat hypertension,32 
but there are no long-term data on cardiovascular events in 
this population.30,32 Because the prevalence of white coat 
hypertension may be higher among adolescents who are 
obese or moderately obese, in the absence of ABPM, white 
coat hypertension may be grossly underdiagnosed in this 
relatively large proportion of individuals. Previously, white 
coat hypertension was thought to be a benign condition, and 
an artifact of anxiousness when patients are in a health care 
facility. However, given the recent left ventricular mass index 
data above and adult data showing other forms of target organ 
damage associated with white hypertension, ABPM follow-up 
has been suggested by pediatric hypertension experts.13
The prevalence of masked hypertension in normotensive 
children and adolescents ranges from 7.6% to 26%.30,33–35 Renal 
transplant recipients are at even greater risk for developing 
masked hypertension.36,37 However, 40% of  adolescents with 
masked hypertension have abnormal  daytime ABPM on 
follow-up, and about 10% go on to develop sustained hyper-
tension and increased left ventricular mass index even prior 
to developing sustained hypertension.30,33,35,38,39 Indeed, the 
higher risk of target organ injury is much better established 
with masked hypertension in adults40 and in children.33,35 
At greater risk for such complications are youths with a triad 
of parental history of hypertension or cardiovascular events, 
a high resting pulse rate, and high body mass index.33 These 
individuals tend to have an activated sympathetic nervous 
system.39,40
Utilizing strict definitions to classify prehypertension 
based on blood pressure load in nonobese children with a 
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mean age of 9.12 years of age without proteinuria or renal 
disease, Lubrano et al found that those with blood pressure 
load .40% had a significantly lower glomerular filtration 
rate and a higher level of proteinuria than control subjects.41 
It was concluded that children with prehypertension defined at 
this blood pressure load limit should have renal function and 
proteinuria measured as an indicator of renal injury related 
to prehypertension. Other studies have also shown that even 
mild elevation in blood pressure in children may result in an 
increased left ventricular mass index and carotid intima-media 
thickness.25–28 Currently, it is not known if lifestyle measures 
or pharmacotherapy can retard proteinuria, overt renal injury, 
or other cardiovascular processes. However, the detrimental 
effect of hypertension on pre-existing chronic kidney disease 
is well established in children and adults.43–45 These effects 
may correlate better with ABPM than with casual blood 
pressure measurements.44,46 For children and adolescents with 
chronic kidney disease, proteinuria, and established hyperten-
sion, a clear benefit followed the use of intensified intervention 
with angiotensin-converting enzyme inhibition to achieve 
mean arterial pressure near the 50th percentile rather than the 
usual goal of blood pressure , the 90th percentile.47
Primary hypertension
The older term for primary hypertension was “essential 
hypertension”. This term is no longer used as a synonym 
for primary hypertension because it incorrectly implies 
a “normal” or “necessary” process. Despite the rising 
prevalence of primary hypertension in childhood, secondary 
hypertension still comprises a much higher proportion com-
pared with adults, 95% of whom have primary hypertension.48 
Thus, exclusion of secondary causes of hypertension is 
particularly important in children presenting with elevated 
blood pressure. The presence of obesity per se should not be 
a reason for not considering secondary causes. While there 
are no absolute differences in the presenting clinical signs 
and symptoms of these two broad classes of hypertension, 
there are several general characteristics which may favor a 
secondary cause (Table 4). Children with secondary causes 
tend to present with Stage II hypertension and be more 
symptomatic than those with primary hypertension. A careful 
medical history, findings on physical examination, and 
several routine laboratory and imaging studies may provide 
more clues to implicate secondary hypertension. The reader 
is also referred to an algorithm that may aid the evaluation 
of hypertension in children.49
Primary hypertension accounts for 48% to 69% of children 
referred for evaluation of hypertension in the US.48,50,51 
It has long been known that primary hypertension arises in 
families. A familial/genetic predisposition to the disorder is 
supported by population studies in natural-adopted children, 
 parent-offspring relationships, and monozygotic-dizygotic 
twins.52 The disorder is widely believed to have a multifac-
torial etiology, with both polygenetic and environmental 
Table 4 General features of children and adolescents suggestive 
of a secondary cause of hypertension
Medical history
•  Family history of secondary disorders of hypertension, hyperlipidemia, 
or cardiovascular events in early life
• Use of medications or drugs contributing to hypertension
• Absence of dietary and other lifestyle risk factors for hypertension
• History of renal or cardiovascular disorders
• Absence of sleep disorders
• Urinary tract infections or unexplained fevers in infancy
•  Symptoms of hypertension: severe recurrent occipital headache, 
cardiac decompensation, acute visual disturbances
Physical examination
• Absence of obesity
• Preadolescence
• Stage ii hypertension with combined systolic and diastolic BP rise
• Retinal vascular changes
• Higher pulse intensity and BP in upper than in lower extremities
• Low pulse rate and blanched or cool skin
• Periumbilical bruit
• Abdominal mass
• Thyromegaly
•   Cutaneous lesions suggestive of specific disorders associated with 
hypertension, such as tuberous sclerosis, neurofibromatosis, Williams 
syndrome, Marfan syndrome, Turner syndrome, Cushing syndrome, 
acanthosis nigricans, skin flushing, pallor, diaphoresis, palpitations
Laboratory studies
• increased serum creatinine concentration
•  Abnormal serum potassium, high calcium, or other electrolyte disorders
• Urinalysis showing pyuria, proteinuria, hematuria, or casts
•  Normal or low serum uric acid level (in the absence of renal dysfunction)
• Low C3, and high ANA, double stranded anti-DNA or ANCA titers
• High fasting serum lipids
•  Abnormal urinary vMA or HvA excretion or high plasma metanephrines
•  Abnormal peripheral plasma renin activity, cortisol, aldosterone, T4, 
thyroid-stimulating hormone
Imaging studies
•  Renal ultrasound showing asymmetry in kidney size, renal masses, 
increased echotexture, hydronephrosis; high arterial resistive indices 
on Doppler study
• Dimercaptosuccinic acid scan showing renal scarring
•  Voiding cystorethrography showing vesicoureteral reflux
•  Magnetic resonance or computer tomography angiography revealing 
renal artery stenosis or aortic coarctation
• Echocardiography
• increased left ventricular mass index; decreased Lv function
Abbreviations: ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic 
antibodies; BP, blood pressure; Lv, left ventricular; vMA, vanillylmandelic acid; 
HvA, homovanillic acid.
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contributions.52,53 Genetic alterations evolve slowly over 
millennia and usually provide a survival advantage in 
response to environmental changes. Hence, genetic influ-
ences alone are unlikely to  contribute substantially to the 
three-fold increase in hypertension over the past century5,53 
or to the much more rapid increase in incidence of hyperten-
sion in adults and adolescents over one decade.5 Thus, the 
obesity epidemic and other lifestyle changes offer better 
explanations for this phenomenon.1–4,6 However, despite the 
strong association between obesity and primary hyperten-
sion, obesity per se is not a necessary prerequisite to the 
development of primary hypertension. Obesity may thus be 
regarded as a trigger for primary hypertension at any age, 
by unmasking an underlying, perhaps genetic, predisposi-
tion for this  disorder. This underscores the need to identify 
and implement healthy dietary and other lifestyle measures 
which may lead to prevention of primary hypertension at a 
young age.
Influence of dietary factors  
on primary hypertension
Sodium/salt
The link between a high salt intake and hypertension is 
indisputable.1,53–58 Several observational epidemiologic 
studies, a meta-analysis,58 as well as the well designed 
INTERSALT study,59 have confirmed the relationship 
between salt and hypertension. More importantly, the ran-
domized Dietary Approaches to Stop Hypertension (DASH) 
study showed that the lower the salt intake the greater the 
blood pressure reduction in both normotensive and hyperten-
sive individuals on a normal North American diet.60
North American children have a high intake of salt, 
derived mainly from processed food rather than salt added to 
food by the individual. Sodium restriction is of particular ben-
efit in African-Americans with salt-sensitive hypertension. 
Figure 1 shows the mechanisms implicated in salt-sensitive 
hypertension.61 Individuals with this disorder have an 
inheritable impairment in sodium excretion at any level 
of renal perfusion pressure. This impairment in “pressure 
natriuresis”, combined with an acquired taste for salt leading 
to ever increasing salt intake, eventually leads to sustained 
hypertension.
The National High Blood Pressure Education Program 
recommends a 1.2 g/day sodium intake for children aged 
4–8 years and 1.5 g/day for older children.11 These limits 
may be difficult to implement. A daily intake of 1.5–2.0 g 
of sodium (4.25–5.0 g of salt) per m2 body surface area 
may be more realistic because children in North America 
average a sodium intake double this amount. The DASH 
diet recommends no added salt, as well as increased fruit 
and vegetables, as well as low fat and low dairy intake.60 
This is a more palatable diet and more likely to succeed in 
the long term.
Potassium/calcium/magnesium
A higher intake of potassium, calcium and magnesium has 
been shown to have an ameliorating effect on blood  pressure 
in both experimental models of hypertension, and in human 
epidemiologic studies.53,56,62 No specific requirements for 
supplemental amounts of potassium, calcium, and magnesium 
are available for hypertensive children.
Caffeine
Caffeine may be viewed either as a beverage or as a drug. 
Currently, it may be among the leading nonprescribed central 
nervous system stimulant drugs associated with hypertension 
in adolescents. Its intake has risen in children in North 
America in parallel with the obesity trend. Many individuals 
are not aware of the large amounts of caffeine found in many 
tea products (70 mg of caffeine per 12 ounces of tea; similar 
amount per 12 ounces of Mountain Dew®). Also, “super-sized” 
volumes of soft drink beverages may contain high caffeine 
amounts along with having a high calorie content. Many 
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Figure 1 Mechanism of salt-sensitive hypertension. Under normal conditions, 
there is a balance between renal perfusion pressure (about 100 mmHg) and 
sodium excretion (about 100–120 mmol/day). The increment in arterial pressure 
is a physiological response directed to promote an increase in urine sodium and 
water excretion required to bring expanded extracellular fluid volume to normal. 
Maintenance  of  hemodynamic  homeostasis  requires  higher  blood  pressure  if  the 
pressure natriuresis mechanism is impaired (shifted to the right and less steep).
Copyright© 2007. Elsevier. Adapted with permission from Rodriguez-iturbe B, 
Romero F, Johnson RJ. Pathophysiological mechanisms of salt-dependent hypertension. 
Am J Kidney Dis. 2007;4:655–672.61
Abbreviation: UNav, urinary sodium excretion. 
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adolescents are also consuming a large amount of caffeine in 
the form of “power drinks”. Caffeine raises systemic blood 
pressure by increasing catecholamine release and peripheral 
vascular resistance.63–65 It also increases pulse rate while 
lowering baroreceptor sensitivity.66,67
Fructose
There is increasing evidence suggesting that fructose 
 consumption $74 g per day is associated with a rise in 
blood pressure in adults and in adolescents.68–70 This effect 
appears to be independent of the link between dietary fructose 
or sugar-sweetened beverages and the obesity epidemic.71 
The exact mechanism of fructose-induced hypertension is 
unknown. Experimental evidence suggests that fructose 
stimulates the sympathetic nervous system, reduces renal 
sodium and fluid excretion, and increases serum uric acid 
levels, which then leads to a direct vascular effect to limit 
nitric oxide or to activate the renin-angiotensin-aldosterone 
system.72,73
Mechanisms of obesity-related 
hypertension
Although significant advances have been made in recent years, 
the mechanisms mediating obesity-related hypertension are 
complex and incompletely understood. Several  interrelated 
clinical conditions and multiple mechanisms may act in concert 
to raise blood pressure.74 For example, there appears to be an 
association between obesity, sleep apnea, and hypertension. 
The mechanisms can be grouped into sympathetic nervous 
system activation, renal mechanisms, hormonal abnormalities, 
and endothelial dysfunction, as shown in Table 5.
 Sympathetic nervous system activation in obesity-related 
primary hypertension has been suggested by a number 
of epidemiological and clinical data. A meta-analysis by 
Goldstein showed higher plasma norepinephrine levels in 
young “essential” hypertensive patients compared with 
normotensive controls in virtually all studies.75 Obese 
young adults were shown to have marked sympathetic 
nerve activation compared with aged-matched lean 
normotensive controls assessed by a microneurographic 
technique after baroreceptor stimulation and deactivation.76 
Furthermore, combined α- and β-adrenergic blockade 
significantly reduced blood pressure in obese hypertensive 
patients compared with lean hypertensive controls, again 
suggesting that increased sympathetic activity is an important 
factor in obesity-related hypertension.77
Several renal mechanisms have been proposed to mediate 
obesity-related hypertension, including impairment of 
pressure natriuresis, activation of the renin-angiotensin-
aldosterone system, and structural changes in the kidney.74 
As discussed earlier and illustrated in Figure 1, pressure 
natriuresis is a homeostatic mechanism whereby excess salt 
and extracellular fluid retention are excreted to reduce venous 
return and cardiac output until blood pressure normalizes. 
Conversely, with hypotension, the kidney retains salt and 
water to increase blood pressure. With obesity, this feedback 
mechanism appears to shift towards an increase in renal tubular 
sodium reabsorption.78 Although the exact pathophysiology 
has not been fully elucidated, hyperinsulinemia and insulin 
resistance, activation of the renin-angiotensin-aldosterone 
system, and increased sympathetic nervous system activity 
could all play a role in this impairment.78
With obesity, studies have shown activation rather than 
the expected suppression of the renin-angiotensin-aldosterone 
system in the setting of sodium retention and extracellular 
fluid expansion.79,80 In one study, individuals with central 
obesity initially had high plasma levels of peripheral renin 
activity, aldosterone, and angiotensin-converting enzyme, 
which improved within six months of gastric bypass 
surgery.79 There appears to be both renal renin-angiotensin-
aldosterone system activation and adipose tissue production 
of renin-angiotensin-aldosterone system hormones. Renal 
renin-angiotensin-aldosterone system activation appears to 
occur via compression of the kidney by perirenal fat that 
elevates interstitial fluid hydrostatic pressure, leading to 
reduced medullary blood flow.81 This results in decreased 
Table 5 Mechanisms of obesity-related hypertension
Sympathetic nervous system activation
Renal mechanisms
•  Shift of pressure natriuresis towards sodium and fluid retention
• Renal renin-angiotensin-aldosterone system activation
•  Renal tissue compression by perirenal fat to induce hyperfiltration
Hormonal abnormalities
• insulin resistance/hyperinsulinemia
• Hyperleptinemia
•  Adipose tissue derived renin-angiotensin-aldosterone system 
activation
• Aberrant adipokines
Endothelial dysfunction
•   Activation of proinflammatory pathways to induce atherosclerotic 
vascular wall changes
•  Reduced vasodilatation due to nitric oxide inactivation and degradation
Note: *This  table  is a simplified  list of mechanisms, and any of  these  factors are 
likely to interact to cause hypertension.
Adolescent Health, Medicine and Therapeutics 2011:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
52
Ellis and Miyashita
sodium detection by the macula densa, leading to increased 
renin secretion, and elevation of blood pressure occurs via 
angiotensin II-induced systemic vasoconstriction, direct 
sodium and water retention, and increased aldosterone 
production.74
In addition to physical compression of the kidneys leading 
to activation of the renal renin-angiotensin-aldosterone 
system, perirenal fat can change the physical structure of the 
kidneys, leading to hyperfiltration, which, over time, induces 
glomerular sclerosis and nephron loss,74 ultimately leading to 
inappropriate alteration in pressure natriuresis and activation 
of the renin-angiotensin-aldosterone system.
There are a number of additional hormonal abnormalities 
associated with obesity which are potentially connected 
with elevation of blood pressure. Hyperinsulinemia, 
as a consequence of insulin resistance, has been linked 
with hypertension mediated by its antinatriuretic effects, 
enhanced sympathetic nervous system activity, augmented 
responses to endogenous vasoconstrictors, altered vascular 
 membrane cation transport, impaired endothelium-dependent 
vasodilatation, and stimulation of vascular smooth muscle 
growth.82 Adipose tissue is increasingly recognized as 
an endocrine organ, with at least 50 different substances 
now identified, and many are implicated in blood pressure 
control.82 Leptin is primarily secreted by adipose tissue, and 
its circulating levels parallel fat cell mass. Its main role is 
to control food intake and energy expenditure.83 It acts on 
receptors in the hypothalamus to regulate energy balance 
by decreasing appetite and increasing energy expenditure 
through sympathetic stimulation.84 Animal studies indicate 
that long-term infusion of leptin raised blood pressure and 
pulse rate, and these increases were abolished after combined 
α- and β-adrenergic blockade.84 Finally, there are adipocyte-
derived peptides, collectively termed adipokines, that may 
also affect blood pressure. One such peptide, adiponectin, 
protects against hypertension via endothelial-dependent 
vasodilatation, and its level falls in obesity-induced insulin 
resistance.82 In addition, another adipokine, resistin, has been 
found to have a positive correlation with elevated blood 
pressure.82
Finally, dysfunction in vascular endothelium  leading 
to changes in systemic vascular resistance is another major 
mechanism of hypertension. There is a growing recognition that 
obesity represents a state of chronic, low-grade inflammation 
leading to various proinflammatory pathways, including 
cytokines interacting with adipokines, leading to atherosclerotic 
vascular wall changes and reduction in endothelium-dependent 
relaxation.85 In addition, obesity contributes to increased 
 oxidative stress and superoxide  production, which are 
associated with nitric oxide inactivation and degradation in the 
vessel wall, leading to reduced vasodilatation.85
Management of primary 
hypertension
Lifestyle and nonpharmacologic measures
Regardless of the etiology of hypertension, pediatricians and 
other health care providers must inquire about environmental 
risk factors that may influence blood pressure, and must 
also obtain a detailed family history in order to assess 
genetic risk. Intervention should start at the prehypertensive 
stage after identifying risk factors, including overweight, 
sleep disorders, exogenous substances that may provoke 
hypertension, excessive participation in video-computer 
games, and assessment of psychosocial factors that may affect 
stress at home and at school. Attention must be given to the 
sodium content of processed food, the amount of fat in the 
diet, and the amount of vegetables and fruit consumed by 
the patient. An overview of the amount and type of exercise 
are an essential part of the medical history. The following is 
a summary of evidence for lifestyle modification to improve 
blood pressure.
Because much of the elevated blood pressure in primary 
hypertension is attributed to obesity and sodium retention, 
current dietary strategies to lower blood pressure are aimed 
at reducing sodium intake and body weight. Reducing dietary 
sodium lessens the demand on the kidneys to excrete enough 
sodium to restore normal blood volume.86 Weight loss will 
also lead to reversal of the pathophysiological pathways 
of obesity and hypertension discussed earlier. The most 
established dietary patterns are the DASH diet,87 variations 
of the DASH diet, and variations of the Mediterranean diet. 
In the original DASH diet trial, 459 adults aged 22 years 
and older with systolic blood pressure ,160 mmHg and 
diastolic blood pressure 80–95 mmHg, were randomly 
assigned to receive eight weeks of the control diet, a diet 
rich in fruit and vegetables, or a “combination” diet rich in 
fruit, vegetables, and low fat dairy products and with reduced 
saturated and total fat, while sodium intake and body weight 
were maintained at constant levels. Among the 133 subjects 
with systolic blood pressure $140 mmHg or diastolic blood 
pressure $90 mmHg, the combination diet (later termed the 
DASH diet) reduced systolic and diastolic blood pressure 
by 11.4 mmHg and 5.5 mmHg more than the control diet, 
 respectively.87 In the subsequent trial with similar partici-
pants and the same ages, 412 participants were randomly 
assigned to either a control diet typical of intake in the US, 
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or the DASH diet with three different levels of sodium, for 
30 consecutive days each, in random order.60 The effects of 
sodium were observed in participants with and without hyper-
tension, in all races and both genders. The DASH diet was 
associated with a significantly lower systolic blood pressure 
at each sodium level. As compared with the control diet with 
a high sodium level, the DASH diet with a low sodium level 
led to a mean systolic blood pressure of 7.1 mmHg lower in 
participants without hypertension, and 11.5 mmHg lower in 
participants with hypertension.60 Similar interventions and 
results for adolescents have also been published.  Fifty-seven 
adolescents, aged 11–18 years with prehypertension or 
Stage I hypertension were randomly assigned to clinic-based 
behavioral nutrition intervention using either the DASH diet 
or routine outpatient hospital-based nutrition care for three 
months, and then had a follow-up assessment three months 
after completion of treatment. Systolic blood pressure Z-score 
showed a statistically significant decline at post-treatment 
and a near statistically significant (P = 0.07) decline at the 
three-month post-intervention follow-up.54
On the other hand, studies have also shown a reduction 
in blood pressure with increased level of activity. The 
relationship has been clearly established in adults, including 
those with obesity.88 This relationship appears to be intact 
in the pediatric age range,89 and the improvement in blood 
pressure appears to correlate with improvement or reversal of 
target organ damage. A three-month randomized controlled 
trial in 44 prepubertal obese children and 22 lean children 
showed significant reductions in systolic and diastolic blood 
pressures, rates of hypertension, office blood pressure, body 
mass index Z-score, abdominal fat, and maximal oxygen 
uptake.90 These improvements correlated with significant 
improvements in arterial stiffness and arterial intima-media 
thickness at six months after the start of intervention. Another 
recent study of subjects aged 5–17 years showed significant 
improvements in 24-hour ABPM and other cardiovascular 
clinical outcomes, including left ventricular mass index, 
prevalence of left ventricular hypertrophy, and carotid 
intima-media thickness, after 12 months of nonpharma-
cological and pharmacological therapy (37 of 86 subjects 
in the study received nonpharmacological therapy, includ-
ing diet modification and increase in physical activity).91 
A literature review on obesity, physical activity, and blood 
pressure recommends 40 minutes of moderate to vigorous 
aerobic-based physical activity 3–5 days per week to reduce 
blood pressure in obese children.89
Based on the aforementioned data, lifestyle changes are 
an integral part in managing all children with prehypertension 
or hypertension. The estimated blood pressure-lowering 
effect in mmHg obtained by implementing several  common 
lifestyle measures is shown in Table 6. A conservative 
nonpharmacologic approach may also serve as the only 
initial intervention in children with Stage I hypertension 
without target organ injury. The aim of treatment is not 
only to lower blood pressure, but also to limit the other 
consequences of an unhealthy lifestyle which may impact 
long-term cardiovascular morbidity and mortality. Apart 
from reducing calories in the overweight and obese, and 
controlling hyperlipidemia, a reduction in salt and caffeine 
intake is appropriate. A balance of calorie intake and exercise 
is essential. Sleep disorders may require special evaluation 
and management. Counseling on the health consequences 
of drug, alcohol, and tobacco use should be reinforced at 
all office or clinic visits. It is essential that education and 
counseling be provided to the entire family and not just the 
child so as to enhance motivation and compliance with the 
proposed treatment plan.
 Setting realistic and measurable goals over specified peri-
ods of time for achieving weight reduction, correction of meta-
bolic disturbances, and numerical targets of blood pressure, 
are useful adjuncts in managing the hypertensive child.
Pharmacologic management  
of primary hypertension
The reader is referred elsewhere for a more comprehensive 
review of the pharmacologic treatment of pediatric 
hypertension.92 There are no large, longitudinal studies to 
provide evidence-based guidelines for the management of 
primary hypertension in children.93 Agents may be chosen 
based on unwanted side effects tailored to the individual 
child’s activities and habits. For example, because β-blockers 
may inhibit reflex tachycardia in children involved in vigorous 
activities, such agents may cause syncope and other adverse 
cardiovascular events. Thus, unlike guidelines for managing 
Table 6 Lifestyle modifications and approximate range of systolic 
blood pressure reduction*
• Exercise/limit television and other sedentary activities (4–9 mmHg)
•  weight reduction (smaller portions/exercise) (5–20 mmHg/10 kg 
weight loss)
•  Consume more fresh vegetables and fruits, low fat dairy products  
and low content of saturated fats (2–8 mmHg)
• Reduce sodium intake (2–8 mmHg)
• Avoid alcohol (2–4 mmHg)
• Limit caffeine
• Avoid tobacco (cigarettes/chewing)
Note: *Obtained from adult studies.
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primary hypertension in adults,7 diuretics and β-blockers are 
rarely employed as initial agents in the control of primary 
hypertension in children. Close monitoring of blood pressure 
is essential in modifying the dosages of antihypertensive 
agents, especially in children with primary hypertension, in 
whom improvements in lifestyle may have a dramatic effect 
in lowering blood pressure.
The combined use of a β-blocker and a thiazide was 
associated with suboptimal blood pressure control in one 
pediatric study of primary hypertension.94 However, hyperten-
sive adolescents with a triad of parental history of hypertension 
or cardiovascular events, a high resting pulse rate, and high 
body mass index, may benefit from such pharmacotherapy to 
reduce blood pressure, particularly if lifestyle measures fail to 
accomplish this goal after a reasonable period of time, such 
as 6–12 months. In children with tachycardia and isolated 
systolic hypertension, noncardioselective β-blockers, such as 
carvedilol, may be more efficacious, and have fewer adverse 
effects on lipid and glucose metabolism than the more cardi-
oselective β-blockers, such as atenolol and metoprolol. Thus, 
use of carvedilol may be advantageous in children with hyper-
tension who are obese and prone to metabolic syndrome.
The use of calcium channel blockers and angiotensin-
converting enzyme inhibitors was examined in a retrospective 
study of primary hypertension in childhood.95 Both classes of 
agents lowered systolic blood pressure, but only angiotensin-
converting enzyme inhibitors also lowered diastolic blood 
pressure. However, when blood pressure below the 95th 
percentile for age, gender, and height was the “target value”, 
only 45% achieved systolic blood pressure control, while 
62.7% achieved diastolic blood pressure control.95
Angiotensin-converting enzyme inhibitors have been 
shown to be as effective as β-blockers and diuretics in 
adults with primary hypertension. Angiotensin-converting 
enzyme inhibitors may also have greater cardioprotective 
benefits which extend beyond blood pressure-lowering, 
whereas several studies indicate an increase in coronary 
artery disease and heart failure with use of calcium channel 
blockers. Although such adverse outcomes are uncommon in 
children managed with calcium channel blockers, the authors 
generally prefer starting with an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker for phar-
macologic management of primary hypertension in children 
and adolescents.
Important outcome measures of managing primary 
hypertension in adults include a reduction in coronary heart 
disease, stroke, and cardiovascular death. No such data are 
available in children.
Goals and general principles  
of hypertension therapy
In asymptomatic children, the National High Blood Pressure 
Education Program11 recommends achieving target blood 
pressure below the 95th percentile if there is no other 
coexisting disorder, and below the 90th percentile in children 
with evidence of coexisting cardiovascular risk factors, 
diabetes, or target organ damage. Hypertension in children 
with overt proteinuria or progressive renal insufficiency is 
also an indication for lowering blood pressure to below the 
90th percentile.
Of immediate concern is the management of acute 
symptoms of hypertension. For example, aggressive and 
immediate pharmacologic control of blood pressure is often 
required in hypertensive children with overt evidence of 
target organ injury in the form of encephalopathy, seizures, 
Bell’s palsy, cerebrovascular accident, congestive heart 
failure, or hypertensive retinopathy.
The long-term objective of hypertension control is the 
prevention of cardiovascular disease and heart failure, which 
remain the leading causes of morbidity and mortality among 
adults in the US. Currently there are no longitudinal studies 
in children assessing the relationship of the level and dura-
tion of hypertension and cardiovascular risk. While numeri-
cal goals are often used to assess the efficacy of therapy, 
isolated blood pressure values obtained at clinic settings 
may be unreliable. Thus, many experts recommend more 
reliable means of predicting cardiovascular complications, 
including ABPM.13,96,97
Reversal of the symptoms and signs of hypertension and 
target organ changes is an even more important goal of therapy. 
Left ventricular hypertrophy on echocardiography is perhaps 
the most sensitive means for detecting target organ injury in 
children with well established hypertension. Left ventricular 
hypertrophy is detected in 40% of such children.18,27,97 
Microalbuminuria, as a marker of microvascular disease, is 
another early clinical indicator of target organ damage in adults 
with hypertension, but its importance has not been investigated 
in children, except in those with type 1 diabetes.
Drug-induced hypertension
Hypertension in response to normal use of prescribed 
medications, abuse of prescribed or over-the-counter 
medications, or use of illicit or illegal drugs, is an important 
cause of secondary hypertension. Hypertension may occur 
with any of the agents listed in Table 7. Also, a genetic 
predisposition to hypertension may be unmasked while pre-
existing hypertension may be exacerbated by use of these 
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agents. Moreover, coadministration of these substances may 
lead to accelerated hypertension.
Among prescribed medications, corticosteroids, such as 
prednisone, used in the management of many autoimmune 
and inflammatory disorders, asthma and other pulmonary 
disorders, and to prevent rejection after transplantation, 
lead the list of drugs that cause hypertension.98 Mechanisms 
for steroid-induced hypertension include a direct miner-
alocorticoid action and suppression of the kallikrein-kinin 
system, resulting in enhanced sensitivity to endogenous 
vasoconstrictors and mineralocorticoids,99 and stimulation 
of angiotensin II type I receptors, resulting in increased 
sodium and fluid retention, and increased cardiac output 
and total peripheral resistance.100 Calcineurin inhibitors, 
such as cyclosporine and tacrolimus, are also utilized for the 
treatment of several of these disorders. The mechanisms of 
hypertension associated with calcineurin inhibitors include 
vasoconstriction of the afferent glomerular arteriole through 
stimulation of the sympathetic nervous system, and local 
release of endothelin-1, resulting in renin release and angio-
tensin II/aldosterone-mediated systemic hypertension.101,102
Increasing numbers of adolescents are receiving oral 
 contraceptive agents to manage dysmenorrhea or for birth 
control purposes. Depending on the estrogen content and 
interplay of dietary and genetic risk factors, or interaction 
with other drugs and vasoactive substances, such adolescents 
may develop symptomatic or asymptomatic hypertension. The 
pathophysiology of estrogen-induced hypertension involves 
stimulation in the  renin-angiotensin-aldosterone  system and 
ensuing sodium and fluid retention.103  Nonsteroidal anti-
inflammatory drugs may cause hypertension by suppress-
ing the synthesis of several important renal  prostaglandins 
which facilitate sodium and fluid excretion as well as 
vasodilation.104
Another group of legal substances that are currently 
abused on a large scale by adolescents are stimulants 
 containing dextroamphetamine, found in numerous cough/
cold/nasal decongestant and asthma medications. According 
to the 2009 Monitoring the Future survey sponsored by 
the National Institute of Drug Abuse, nearly 6% of all 
youth in the 10th and 12th grades had abused such drugs 
over the  preceding year (www.drugabuse.gov). These 
 over- the-counter medications are readily available and 
relatively inexpensive. They are used recreationally and 
produce a state of euphoria or “high”. Dextroamphetamine 
is also found in Dexedrine® and Aderall®, while meth-
ylphenidate, which has a similar effect, is found in Ritalin® 
and Concerta®. Dextroamphetamine can also be purchased 
in bulk powder over the Internet. While their prescribed use 
is safe and effective, when abused, these agents raise brain 
norepinephrine and dopamine concentrations, and also result 
in systemic tachycardia, vasoconstriction, and hypertension. 
Similarly, illicit drugs, such as ecstasy (3,4 methylene-
dioxymethamphetamine), monoamine oxidase inhibitors, 
such as tranylcypromine and other antidepressants, and 
cocaine may cause acute hypertension by stimulation of 
α-adrenergic action (catecholamine release), resulting in 
acute tachycardia and vasoconstriction.105 Hypertension 
in individuals with cocaine intoxication or monoamine 
oxidase inhibitor crisis may be controlled by α-adrenergic 
blockers while avoiding the initial use of β-blockers which 
may potentiate the α-adrenergic action of catecholamines. 
Cocaine may also cause hypertension through chronic kidney 
injury.106 Despite being banned by the US Food and Drug 
Administration, children and adolescents illegally use central 
Table 7 Partial list of exogenous substances that raise blood 
pressure
Substance Raise BP Interfere  
with therapy
Source of 
substance
Anabolic steroids Yes No Patient
Caffeine Yes No Patient
Cocaine Yes Yes Patient
Ethanol Yes No Patient
Ephedra Yes Yes Patient
Nicotine Yes No Patient
Sodium chloride Yes Yes Patient
Sympathomimetic  
agents
Yes No Patient or  
clinician
Nonsteroidal anti- 
inflammatory agents
Yes Yes Patient or  
clinician
Chlorpromazine Yes No Clinician
Corticosteroids Yes Yes Clinician
Cyclosporine Yes No Clinician
Tacrolimus Yes No Clinician
Erythropoietin Yes No Clinician
Monoamine oxidase  
inhibitors
Yes No Clinician
Oral contraceptives Yes No Clinician
Tricyclic  
antidepressants
Yes No Clinician
Strattera® Yes No Clinician
Concerta® Yes No Clinician
Adderall® Yes No Clinician
wellbutrin® Yes No Clinician
Ritalin® Yes Yes Clinician
Dexedrine® Yes Yes Patient or  
Clinician
Ecstasy Yes Yes Patient
β-adrenergic agonists Yes Yes Clinician
Theophylline Yes No Clinician
Phencyclidine Yes No Clinician
Abbreviation: BP, blood pressure.
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nervous stimulants containing ephedra or ephedrine or a 
similar stimulant, bitter orange. These children are at risk for 
hypertension through catecholamine release and stimulation 
of α-, β1-, and β2-adrenergic receptors.106
Other commonly prescribed drugs include erythropoietin, 
used to manage anemia associated with chronic renal  failure 
and other disorders. Apart from increasing hematocrit, 
erythropoietin increases sensitivity to endogenous vasopres-
sors, and may have a direct vasopressor and trophic effect 
on vessels.107,108
Although there are legitimate beneficial effects of 
anabolic steroids in cancer and other patients, these agents 
are often used inappropriately for nonmedical purposes, 
such as muscle building and for enhancing general athletic 
performance. These may cause hypertension through their 
testosterone-like effects.
Among dietary and herbal stimulants, the influence of 
caffeine in inducing hypertension has already been  discussed. 
Large amounts of caffeine are responsible for the stimulating 
effect of many popular “energy drinks” such as Nitric 
Oxide System®, 5-Hour Energy®, Battery Energy Shot®, 
and Cocaine®. The herbal extract, yohimbine, is often used 
as an aid to erectile dysfunction and an aid to weight loss. 
It is also a stimulant that raises plasma norepinephrine levels 
while lowering presynaptic α
2
-adrenergic blockade, leading 
to tachycardia and hypertension.109
According to the 2009 Monitoring the Future survey, 
alcohol and cigarette use are by far the most common habits 
among adolescents. Among high school seniors, 36.5% had 
used an illicit drug during the preceding year, 4.7% had 
used cocaine or crack cocaine, and 5.5% had used ecstasy 
or methamphetamines over the preceding year, while 5.2% 
had used marijuana on a daily basis. These trends have been 
relatively unchanged over the past five years.
Ethanol induces hypertension by blunting the blood 
pressure response of plasma renin activity to changes in 
sodium intake.110 Chronic tobacco use has several  detrimental 
effects on the vascular endothelium and arterial wall 
thickening, resulting in decreased vasodilation and increased 
total peripheral resistance and hypertension.111,112
Pregnancy-associated hypertension
Approximately 750,000 women younger than 20 years of age 
become pregnant in the US each year. The estimated teenage 
pregnancy rate in 2006 was 71.5 per 1000 women aged 
15–19 years, or 7% of this age group 113 New-onset hypertension 
may occur in up to 8% of pregnancies.114,115 Adolescents have a 
significant higher risk for pregnancy-associated hypertension 
and for having small for gestational age offspring who may 
also be susceptible to hypertension. Gestational hypertension 
in adolescents may also be a forerunner to development of 
sustained maternal hypertension 6–9 years after pregnancy.
The spectrum of hypertension during pregnancy includes 
pre-eclampsia (more common, associated with proteinuria), 
eclampsia (less common, associated with proteinuria and 
seizures), and gestational hypertension (no proteinuria).
The incidence of pre-eclampsia has risen by 40% in 
the past 10–20 years.115,116 The condition typically presents 
with proteinuria, edema, headache, emesis, abdominal pain, 
and visual disturbances after 20 weeks of pregnancy. Risk 
factors for the disorder include obesity, a large gap between 
pregnancies, multiparity, and teenage pregnancy. Also, 
pre-eclampsia during a previous pregnancy increases the 
subsequent risk from 3.3% to 20%. Pre-existing hypertension 
and renal disease are important risk factors in 30% of women 
who develop pre-eclampsia. Moreover, 20% of women 
with eclampsia will go on to develop sustained systemic 
hypertension after pregnancy.
The pathogenesis of pre-eclampsia and its more serious 
form, eclampsia, is partly elucidated. According to the 
leading hypothesis, a reduction in uteroplacental blood flow 
related to abnormal arterioles in the cytotrophoblast may 
initiate placental ischemia. This then leads to synthesis and 
release of proangiogenic factors and vasoactive substances 
which favor aberrant local and systemic vasoconstriction 
rather than the physiologic vasodilation and blood volume 
expansion observed during normal pregnancy. Elevated 
plasma concentrations of vasocontrictive thromboxane and 
endothelin-1 and reduction in vasodilatory prostaglandins and 
nitric oxide have been found in this disorder.116,117 Also, there 
is an increase in proinflammatory cytokines, tumor necrosis 
factor-α, and interleukins 1 and 6, which stimulate endothelin 
synthesis but reduce acetylcholine-mediated vasodilation, all 
of which favor the development of hypertension.118–121
Experimental evidence also implicates prolonged 
inhibition of nitric oxide synthase in the pathogenesis of 
eclampsia-associated hypertension.122,123 This leads to loss 
of modulation of vasoconstrictor substances, resulting in 
renal and systemic vasoconstriction, proteinuria, intrauterine 
growth retardation, and high fetal morbidity, similar to that 
encountered in humans with this disorder.
A rare and intriguing monogenic disorder predisposing to 
pre-eclampsia and eclampsia has also been described with a 
gain of function mutation of the mineralocorticoid receptor 
of the principal renal tubular cells.124 This mutant receptor is 
activated by the high plasma concentrations of progesterone 
Adolescent Health, Medicine and Therapeutics 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
57
Hypertension in older children and adolescents
prevailing during pregnancy, thereby resulting in pathologic 
increases in sodium retention, volume expansion, and 
hypertension. Because spironolactone inhibits the wild-type 
mineralocorticoid receptor, but tends to activate the mutant 
receptor, this agent may promote rather than reduce blood 
pressure in this disorder.
Although pre-eclampsia usually resolves after delivery 
of the infant and placenta, it is desirable to manage the 
hypertension until at least 32 weeks of gestation so as to 
limit the complications of prematurity to the fetus. Pro-
vided there is no target organ damage, as a general rule, a 
higher threshold for treatment may be used (usually dia-
stolic blood pressure .100 mmHg and/or systolic blood 
 pressure .160 mmHg), because lower placental blood flow 
may compromise growth and overall safety of the infant. 
The goal of therapy is a diastolic blood pressure below 
90 mmHg. Drugs that do not affect placental blood flow are 
recommended.125 Alpha-methyldopa may be an initial agent, 
and hydralazine is another such agent. Angiotensin-converting 
enzyme inhibitors and angiotensin receptor blockers should 
not be use to manage pregnancy-associated hypertension 
because of teratogenic events noted as early as the first tri-
mester of pregnancy that was previously thought to be a safe 
period.126 Birth defects include cardiovascular and neurologic 
complications, craniofacial deformities, and renal dysplasia, 
leading to renal insufficiency and oligohydramnios.
In individuals nearing delivery, prophylaxis against 
seizures (eclampsia) is essential during labor and for 1–2 days 
after delivery. This consists of intravenous magnesium 
sulfate, starting with a 4 g loading dose (over 15–20 minutes), 
followed by 2 g per hour by continuous infusion thereafter. 
The goal is to achieve high (6 mg/dL) but nontoxic blood 
magnesium levels.
Video/computer games  
and blood pressure
A telephone survey published in 2004 found a mean daily 
video game usage of 1.1 hours and computer game usage of 
0.54 hours in children younger than 11 years.127 In a similar 
study, 8–18-year-olds played an average of 1.21 hours of 
video games per day, and the average time was even longer 
in boys, at 1.61 hours per day.128 Recent investigations have 
linked cardiovascular responses to acute stressors, including 
video game playing, with both immediate and future blood 
pressure elevation. Among 88 healthy youngsters aged 
7–13 years, born to at least one parent with primary hyperten-
sion, elevated systolic blood pressure responses to an acute 
stress from five minutes of video game playing was predictive 
of higher systolic blood pressure by ABPM 2.5 years later.129 
A recent report in healthy German boys aged 12–14 years, 
using more updated video games with complicated control-
lers, demonstrated systolic and diastolic blood pressures rise 
exceeding two standard deviations in 14 of 17 subjects during 
12 minutes of playing.130 Further, this study also found similar 
systolic and higher diastolic blood pressures, despite less 
energy consumption during video game playing compared 
with riding a bicycle  ergometer.130 Thus, these studies sug-
gest that video game playing not only contributes to a more 
sedentary lifestyle with less energy consumption, but it also 
intrinsically elevates blood pressure acutely, and may lead to 
development of sustained elevated blood pressure in the long 
run. Finally, a recent study in 25 boys and 23 girls aged 13–16 
years reported that the systolic blood pressure response while 
preparing and giving speeches was independently predictive 
of carotid intima-media thickness.131 Although we are unaware 
of any study linking video game playing with hypertension-
related target organ changes, based on the above studies, 
one may postulate that individuals involved in extended and 
habitual video game playing may be exposed to recurrent 
excitement and acute stress responses that may potentially 
lead to hypertension-related target organ damage.
Hypertension in athletes
Systemic hypertension is the most common cardiovascular 
condition observed in competitive athletes,132 many of whom 
are adolescents. Almost 80% of adolescent athletes with blood 
pressure , 142/92 mmHg during sports preseason screening 
examination eventually developed sustained hypertension.133 
Unique to conditioned athletes are two phenomena that can 
lead to isolated systolic hypertension. Foremost is the fact 
that the “athlete’s heart” is characterized by a high rest-
ing stroke volume and cardiac output, and low peripheral 
resistance and heart rate.134 These individuals may have a 
high pulse pressure and systolic blood pressure, often in the 
range of prehypertension, and occasionally in the range of 
Stage I hypertension, while diastolic blood pressure is in 
the normal range due to a higher resting stroke volume and 
cardiac output.135 The other phenomenon is spurious systolic 
hypertension, felt to result from exaggerated pulse pressure 
amplification in the arm.136 The latter occurs as a result of the 
progressive decrease in arterial diameter from the heart to 
the arm and the corresponding increase in arterial impedance, 
resulting in aortic systolic pressure being normal and up to 
30–40 mmHg lower than brachial systolic pressure. Although 
the long-term cardiovascular significance of this is unknown, 
it may reflect greater stoke volume in athletes.136
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The American Academy of Pediatrics recently released a 
policy statement regarding athletic participation by children 
and adolescents with hypertension.137 Regular exercise has 
been shown to help reduce both systolic and diastolic blood 
pressure, thus regular physical activity is encouraged in 
those with hypertension.11 However, given reports of cere-
brovascular accidents during maximal exercise, the American 
Academy of Pediatrics policy recommends temporary activity 
restric tion for athletes who have Stage II hypertension until 
normal blood pressure is achieved.137
There are two classes of exercises which may affect 
blood pressure differently. Dynamic exercise involves 
changes in muscle length and joint movement, with rhythmic 
contractions that develop relatively small intramuscular force. 
In contrast, static exercise involves development of relatively 
large intramuscular force with little or no change in muscle 
IIIA
(Moderate)
Bobsledding/luge*†
Field events (throwing)
Gymnastics*†
Martial arts*
Sailing
IIIB
(High moderate)
Body building*†
Downhill skiing*†
Skateboarding*†
Snowboarding*†
Wrestling*
IIIC
(High)
Boxing*∇
Canoeing/kayaking
Cycling*†
Decathlon
Rowing
Speed-skating*†
Triathlon*†
Sport climbing
Waterskiing*†
Weightlifting*†
Windsurfing*†
IIA
(Low moderate)
Archery
Auto racing*†
Diving*†
Equestrian*†
Motorcycling*†
IIB
(Moderate)
American football*
Field events (jumping)
Figure skating*
Rodeoing*†
Rugby*
Running (sprint)
Surfing*†
Synchronized swimming†
IIC
(High moderate)
Basketball*
Ice hockey*
Cross-country skiing
(skating technique)
Lacrosse*
Running (middle distance)
Swimming
Team handball
IA
(Low)
Billiards
Bowling
Cricket+
Curling
Golf
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Figure 2 Classification of sports according to cardiovascular demands (based on combined static and dynamic components). This classification is based on peak static and 
dynamic components achieved during competition. However, it should be noted that higher values may be reached during training. The increasing dynamic component is 
defined in terms of the estimated percent of maximal oxygen uptake achieved, and results in an increasing cardiac output. The increasing static component is related to the 
estimated percent of MvC reached and results in an increasing blood pressure load. The lowest total cardiovascular demands (cardiac output and blood pressure) are shown 
in Box iA and the highest are shown in Box iiiC. Boxes iiA, iB, iiiA, iiB, iC, iiiB and iiC depict low-moderate, moderate, and high-moderate total cardiovascular demands. 
These categories progress diagonally across the table from lower left to upper right.
Notes: *Danger of bodily collision; †increased risk if syncope occurs; ∇Participation not recommended by the American Academy of Pediatrics; +The American Academy of 
Pediatrics classifies cricket in the IB box (low static, moderate dynamic). 
Copyright© 2010. Elsevier. Adapted with permission from McCambridge TM, Benjamin HJ, Brenner JS, et al. Athletic participation by children and adolescents who have 
systemic hypertension. Pediatrics. 2010;125:1287–1294.137 
Abbreviations: HTN, hypertension; MvC, maximal voluntary contraction.
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length or joint movement.138 Most physical activities involve 
both dynamic and static components to varying degrees. 
For example, long distance running has high dynamic and 
low static components, weight lifting has low dynamic and 
high static components, and boxing has both high dynamic 
and static components. Dynamic exercise causes a marked 
increase in oxygen consumption, cardiac output, heart rate, 
stroke volume, and systolic blood pressure, as well as a 
moderate increase in mean arterial pressure and a decrease 
in diastolic blood pressure and total peripheral resistance. 
In contrast, static exercise causes a small increase in oxygen 
consumption, cardiac output, and heart rate, with no change 
in stroke volume, a marked increase in systolic and diastolic 
blood pressure and mean arterial pressure, and no appreciable 
change in total peripheral resistance.138 The concern with 
static exercise is the acute increase in diastolic blood pressure 
and possible increase in muscle mass that may elevate resting 
blood pressure. Thus, the expert opinion is to be more cau-
tious in athletes with Stage II hypertension who participate 
in more static exercise, although limited evidence show no 
greater risk with highly static exercise.137
Figure 2 shows various sports classified according to 
cardiovascular demands. The American Academy of Pediatrics 
recommendations include no limitation of competitive athlet-
ics for youths with prehypertension or Stage I hypertension in 
the absence of end organ damage, including left ventricular 
hypertrophy or concomitant heart disease. For youths with 
Stage II hypertension without end organ damage, the Ameri-
can Academy of Pediatrics recommends restrictions on highly 
static sports (classes IIIA and IIIC in Figure 2) until their 
blood pressure normalizes after therapy.137
When evaluating adolescent athletes for hypertension, 
particular attention should be paid to not only their diet and 
activity, but to other potential behavioral contributors to ele-
vated blood pressure, including use of alcohol, caffeine, drugs 
(cocaine and stimulants), tobacco, nonsteroidal anti-inflamma-
tory drugs, human growth hormone, erythropoietin, anabolic 
steroids, diet pills, and herbal supplements.136  Adolescent 
females should also be questioned about oral contraceptive 
use, given that about 5% develop elevated blood pressure 
over a five-year period.136 Lastly, attention must be paid if the 
decision is made to treat hypertension with antihypertensive 
agents. The World Anti-Doping Agency, the US Olympic Com-
mittee, and the National Collegiate Athletic Association have 
banned several antihypertensive medications.136 Beta-blockers 
are banned in precision sports, such as archery, shooting, golf, 
and skiing.139 Also, all diuretics are banned because they can 
mask the presence of anabolic steroids.139
Conclusion
Hypertension in the pediatric population may soon comprise 
20% of the estimated 60–75 million of the US population with 
hypertension. The potential health consequences and financial 
cost to society related to this disorder could be staggering, 
and are just beginning to unfold. With proper education on 
hypertension and its harmful effects in children, pediatricians 
will assume a more pivotal role in the early detection of 
hypertension and be in an ideal position to institute preventive 
measures, particularly in the adolescent population.
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